YUTIQ (Fluocinolone Acetonide) for treatment of chronic non-infectious uveitis

YUTIQ or fluocinolone acetonide intravitreal implant 0.18 mg is indicated for the treatment of chronic non-infectious uveitis that affects the posterior segment of the eye.

Hypersensitivity: YUTIQ is contraindicated in patients with known hypersensitivity to this product.

Ocular or Periocular Infections: YUTIQ is contraindicated in patients with active or suspected ocular or periocular infections including most viral disease of the cornea and conjunctiva including vaccinia, mycobacterial infections, varicella, active epithelial herpes simplex keratitis (dendritic keratitis), and fungal diseases.

Intravitreal Injection-related Effects: Intravitreal injections, including YUTIQ, have been associated with increased or decreased intraocular pressure, endophthalmitis, eye inflammation, and choroidal or retinal detachments. Hypotony has also been observed within 24 hours of injection and it has resolved within 2 weeks. Patients should be monitored after the intravitreal injection.

Risk of Implant Migration: Patients in whom the posterior capsule of the lens is absent or has a tear are at risk of implant migration into the anterior chamber.

Steroid-related Effects: The use of corticosteroids including YUTIQ may produce increased intraocular pressure, posterior subcapsular cataracts, and glaucoma. It may also enhance the establishment of secondary ocular infections due to fungi, bacteria, or viruses. It is not recommended to be used in patients with a history of ocular herpes simplex because of reactivation of the viral infection.

In controlled studies, the most commonly reported adverse reactions were cataract development and an increase in intraocular pressure.

Other side effects were visual acuity reduced, macular edema, uveitis, conjunctival hemorrhage, eye pain, hypotony of eye, anterior chamber inflammation, dry eye, vitreous opacities, conjunctivitis, posterior capsule opacification, ocular hyperemia, vitreous haze, foreign body sensation In Eyes, vitritis, vitreous floaters, eye Pruritus, conjunctival hyperemia, ocular discomfort, macular fibrosis, glaucoma, photopsia, vitreous hemorrhage, iridocyclitis, eye inflammation, choroiditis (ask your doctor for more information).

Administration: The intravitreal injection administration is carried out under aseptic conditions, which would include the use of a sterile drape, sterile caliper, sterile gloves, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide should be given before the use of the injection.

Following the injection, You will be monitored for changes in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for tonometry within 30 minutes following the injection perfusion of the optic nerve head immediately after the injection, and biomicroscopy between two and seven days following the injection. You should go to the doctor right away if you see any symptoms suggestive of endophthalmitis.

If the eye becomes red, painful, sensitive to light, or develops a change in vision, you should seek immediate care from an ophthalmologist.

You may experience temporary visual blurring after receiving an intravitreal injection, so make sure to drive or use any machine until it goes away.

It is not known whether YUTIQ can cause fetal harm. It is also not known whether YUTIQ can be absorbed into the human milk, or affect breastfed infants, and milk production.